Lyell Immunopharma initiated with a Buy at Lucid Capital

Lucid Capital analyst Christopher Liu initiated coverage of Lyell Immunopharma (LYEL) with a Buy rating and $20 price target Lyell is a clinical-stage biotechnology company focused on developing potentially curative cell therapies for cancer patients, the analyst tells investors in a research note. The firm sees peak sales of $2.2B by 2039 for the company’s lead asset ronde-cel in diffuse large B-cell lymphoma. The market is competitive, but there is room for several assets in the space given the meaningfully large opportunity, contends Lucid.